Tokyo, Oct. 14 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059380) titled 'Evaluation of the immune effects of High-Intensity Focused Ultrasound (HIFU) in Prostate Cancer' on Oct. 14.
Study Type:
Observational
Primary Sponsor:
Institute - Tokai University School of Medicine
Condition:
Condition - Prostate cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The aim of this study is to compare antitumor immune responses induced by HIFU with those induced by other treatment modalities in patients with localized prostate cancer.
Basic objectives2 - Bio-availability
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male
Key inclusion criteria - 1. Patients diagnosed with non-metastatic prostate cancer who, after receiving a thorough explanation of treatment options from their attending physician, have chosen either HIFU or RARP; and patients diagnosed with benign prostatic hyperplasia who, after receiving a thorough explanation of treatment options from their attending physician, have chosen TUR-P.
2. Individuals with a PSA level below 20 ng/mL.
3. Individuals who, after receiving sufficient explanation regarding participation in this study, have provided written informed consent of their own free will.
Key exclusion criteria - 1. Individuals receiving hormonal therapy.
2. Individuals from whom informed consent could not be obtained.
3. Other individuals deemed inappropriate for the study by the principal investigator or sub-investigators.
Target Size - 20
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2021 Year 09 Month 14 Day
Date of IRB - 2021 Year 09 Month 14 Day
Anticipated trial start date - 2021 Year 09 Month 14 Day
Last follow-up date - 2024 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067913
Disclaimer: Curated by HT Syndication.
